Lung cancer and lung injury

The dual role of ceramide

Tzipora Goldkorn, Samuel Chung, Simone Filosto

Research output: Chapter in Book/Report/Conference proceedingChapter

21 Citations (Scopus)

Abstract

Sphingolipids play key roles in cancer, yet our current understanding of sphingolipid function in lung cancer is limited to a few key players. The best characterized of these are sphingosine-1-phoshate and ceramide which are described for their opposing roles in cell fate. However, because sphingolipids as a whole are readily interconverted by a complex enzymatic machinery, no single sphingolipid appears to have exactly one role. Instead, the roles of specific sphingolipids appear to be context specific as demonstrated by findings that ceramide-1-phosphate has both proliferative and apoptotic effects depending on its concentration. Therefore, we present herein several years of research on ceramide, a sphingolipid linked to apoptotic signaling, that is emerging in cancer research for its potential roles in proliferation and cell-to-cell communication via exosomes. Ceramide is a well-studied sphingolipid in both normal and pathological conditions ranging from skin development to lung cancer. Interestingly, several groups have previously reported its increased levels in emphysema patients who are smokers, a patient subpopulation greatly susceptible to lung cancer. However, the molecular mechanisms through which cigarette smoke (CS) and ceramide accumulation lead to lung cancer, non-small cell lung cancer (NSCLC) specifically, are unknown. Interestingly, recent studies clearly establish that two signaling pathways are activated during CS exposure in the lung airway. One centers on the activation of neutral sphingomyelinase2 (nSMase2), an enzyme that hydrolyzes sphingomyelin to ceramide. The other pathway focuses on the oncogenic EGF receptor (EGFR), which becomes aberrantly activated but not degraded, leading to prolonged proliferative signaling. Recent studies show that these two signaling pathways may actually converge and integrate. Specifically, Goldkorn et al. demonstrated that during CS exposure, EGFR is favorably co-localized in ceramide-enriched regions of the plasma membrane, proposing that nSMase2/ceramide plays a role in the aberrant EGFR activation, leading to augmented tumorigenic signaling. Moreover, new findings indicate that CS exposure may induce resistance to the tyrosine kinase inhibitors (TKIs), used for treatment of NSCLC, merely through posttranslational molecular alterations. Furthermore, structural anomalies of the CS-activated EGFR appear to be supported by the excess ceramide produced by the CS-activated nSMase2 in the plasma membrane of lung epithelial cells. We present in this chapter the progression of the sphingolipid field in lung cancer using ceramide as an example. However, many crucial questions remain to be answered regarding the role of sphingolipids in lung cancer because of the glut of promising observations.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
Pages93-113
Number of pages21
Volume216
DOIs
StatePublished - 2013

Publication series

NameHandbook of Experimental Pharmacology
Volume216
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Sphingolipids
Ceramides
Lung Injury
Lung Neoplasms
Smoke
Tobacco Products
Epidermal Growth Factor Receptor
Cell membranes
Non-Small Cell Lung Carcinoma
Chemical activation
Cells
Cell Membrane
Exosomes
Lung
Sphingosine
Sphingomyelins
Emphysema
Research
Cell Communication
Protein-Tyrosine Kinases

Keywords

  • Ceramide
  • Cigarette smoke
  • Egfr
  • Lung cancer and injury
  • Neutral sphingomyelinase 2
  • Oxidative stress
  • Sphingolipids

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Goldkorn, T., Chung, S., & Filosto, S. (2013). Lung cancer and lung injury: The dual role of ceramide. In Handbook of Experimental Pharmacology (Vol. 216, pp. 93-113). (Handbook of Experimental Pharmacology; Vol. 216). https://doi.org/10.1007/978-3-7091-1511-4-5

Lung cancer and lung injury : The dual role of ceramide. / Goldkorn, Tzipora; Chung, Samuel; Filosto, Simone.

Handbook of Experimental Pharmacology. Vol. 216 2013. p. 93-113 (Handbook of Experimental Pharmacology; Vol. 216).

Research output: Chapter in Book/Report/Conference proceedingChapter

Goldkorn, T, Chung, S & Filosto, S 2013, Lung cancer and lung injury: The dual role of ceramide. in Handbook of Experimental Pharmacology. vol. 216, Handbook of Experimental Pharmacology, vol. 216, pp. 93-113. https://doi.org/10.1007/978-3-7091-1511-4-5
Goldkorn T, Chung S, Filosto S. Lung cancer and lung injury: The dual role of ceramide. In Handbook of Experimental Pharmacology. Vol. 216. 2013. p. 93-113. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-7091-1511-4-5
Goldkorn, Tzipora ; Chung, Samuel ; Filosto, Simone. / Lung cancer and lung injury : The dual role of ceramide. Handbook of Experimental Pharmacology. Vol. 216 2013. pp. 93-113 (Handbook of Experimental Pharmacology).
@inbook{139e704fdfa04b538966d05ea3e03fd9,
title = "Lung cancer and lung injury: The dual role of ceramide",
abstract = "Sphingolipids play key roles in cancer, yet our current understanding of sphingolipid function in lung cancer is limited to a few key players. The best characterized of these are sphingosine-1-phoshate and ceramide which are described for their opposing roles in cell fate. However, because sphingolipids as a whole are readily interconverted by a complex enzymatic machinery, no single sphingolipid appears to have exactly one role. Instead, the roles of specific sphingolipids appear to be context specific as demonstrated by findings that ceramide-1-phosphate has both proliferative and apoptotic effects depending on its concentration. Therefore, we present herein several years of research on ceramide, a sphingolipid linked to apoptotic signaling, that is emerging in cancer research for its potential roles in proliferation and cell-to-cell communication via exosomes. Ceramide is a well-studied sphingolipid in both normal and pathological conditions ranging from skin development to lung cancer. Interestingly, several groups have previously reported its increased levels in emphysema patients who are smokers, a patient subpopulation greatly susceptible to lung cancer. However, the molecular mechanisms through which cigarette smoke (CS) and ceramide accumulation lead to lung cancer, non-small cell lung cancer (NSCLC) specifically, are unknown. Interestingly, recent studies clearly establish that two signaling pathways are activated during CS exposure in the lung airway. One centers on the activation of neutral sphingomyelinase2 (nSMase2), an enzyme that hydrolyzes sphingomyelin to ceramide. The other pathway focuses on the oncogenic EGF receptor (EGFR), which becomes aberrantly activated but not degraded, leading to prolonged proliferative signaling. Recent studies show that these two signaling pathways may actually converge and integrate. Specifically, Goldkorn et al. demonstrated that during CS exposure, EGFR is favorably co-localized in ceramide-enriched regions of the plasma membrane, proposing that nSMase2/ceramide plays a role in the aberrant EGFR activation, leading to augmented tumorigenic signaling. Moreover, new findings indicate that CS exposure may induce resistance to the tyrosine kinase inhibitors (TKIs), used for treatment of NSCLC, merely through posttranslational molecular alterations. Furthermore, structural anomalies of the CS-activated EGFR appear to be supported by the excess ceramide produced by the CS-activated nSMase2 in the plasma membrane of lung epithelial cells. We present in this chapter the progression of the sphingolipid field in lung cancer using ceramide as an example. However, many crucial questions remain to be answered regarding the role of sphingolipids in lung cancer because of the glut of promising observations.",
keywords = "Ceramide, Cigarette smoke, Egfr, Lung cancer and injury, Neutral sphingomyelinase 2, Oxidative stress, Sphingolipids",
author = "Tzipora Goldkorn and Samuel Chung and Simone Filosto",
year = "2013",
doi = "10.1007/978-3-7091-1511-4-5",
language = "English (US)",
isbn = "9783709115107",
volume = "216",
series = "Handbook of Experimental Pharmacology",
pages = "93--113",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Lung cancer and lung injury

T2 - The dual role of ceramide

AU - Goldkorn, Tzipora

AU - Chung, Samuel

AU - Filosto, Simone

PY - 2013

Y1 - 2013

N2 - Sphingolipids play key roles in cancer, yet our current understanding of sphingolipid function in lung cancer is limited to a few key players. The best characterized of these are sphingosine-1-phoshate and ceramide which are described for their opposing roles in cell fate. However, because sphingolipids as a whole are readily interconverted by a complex enzymatic machinery, no single sphingolipid appears to have exactly one role. Instead, the roles of specific sphingolipids appear to be context specific as demonstrated by findings that ceramide-1-phosphate has both proliferative and apoptotic effects depending on its concentration. Therefore, we present herein several years of research on ceramide, a sphingolipid linked to apoptotic signaling, that is emerging in cancer research for its potential roles in proliferation and cell-to-cell communication via exosomes. Ceramide is a well-studied sphingolipid in both normal and pathological conditions ranging from skin development to lung cancer. Interestingly, several groups have previously reported its increased levels in emphysema patients who are smokers, a patient subpopulation greatly susceptible to lung cancer. However, the molecular mechanisms through which cigarette smoke (CS) and ceramide accumulation lead to lung cancer, non-small cell lung cancer (NSCLC) specifically, are unknown. Interestingly, recent studies clearly establish that two signaling pathways are activated during CS exposure in the lung airway. One centers on the activation of neutral sphingomyelinase2 (nSMase2), an enzyme that hydrolyzes sphingomyelin to ceramide. The other pathway focuses on the oncogenic EGF receptor (EGFR), which becomes aberrantly activated but not degraded, leading to prolonged proliferative signaling. Recent studies show that these two signaling pathways may actually converge and integrate. Specifically, Goldkorn et al. demonstrated that during CS exposure, EGFR is favorably co-localized in ceramide-enriched regions of the plasma membrane, proposing that nSMase2/ceramide plays a role in the aberrant EGFR activation, leading to augmented tumorigenic signaling. Moreover, new findings indicate that CS exposure may induce resistance to the tyrosine kinase inhibitors (TKIs), used for treatment of NSCLC, merely through posttranslational molecular alterations. Furthermore, structural anomalies of the CS-activated EGFR appear to be supported by the excess ceramide produced by the CS-activated nSMase2 in the plasma membrane of lung epithelial cells. We present in this chapter the progression of the sphingolipid field in lung cancer using ceramide as an example. However, many crucial questions remain to be answered regarding the role of sphingolipids in lung cancer because of the glut of promising observations.

AB - Sphingolipids play key roles in cancer, yet our current understanding of sphingolipid function in lung cancer is limited to a few key players. The best characterized of these are sphingosine-1-phoshate and ceramide which are described for their opposing roles in cell fate. However, because sphingolipids as a whole are readily interconverted by a complex enzymatic machinery, no single sphingolipid appears to have exactly one role. Instead, the roles of specific sphingolipids appear to be context specific as demonstrated by findings that ceramide-1-phosphate has both proliferative and apoptotic effects depending on its concentration. Therefore, we present herein several years of research on ceramide, a sphingolipid linked to apoptotic signaling, that is emerging in cancer research for its potential roles in proliferation and cell-to-cell communication via exosomes. Ceramide is a well-studied sphingolipid in both normal and pathological conditions ranging from skin development to lung cancer. Interestingly, several groups have previously reported its increased levels in emphysema patients who are smokers, a patient subpopulation greatly susceptible to lung cancer. However, the molecular mechanisms through which cigarette smoke (CS) and ceramide accumulation lead to lung cancer, non-small cell lung cancer (NSCLC) specifically, are unknown. Interestingly, recent studies clearly establish that two signaling pathways are activated during CS exposure in the lung airway. One centers on the activation of neutral sphingomyelinase2 (nSMase2), an enzyme that hydrolyzes sphingomyelin to ceramide. The other pathway focuses on the oncogenic EGF receptor (EGFR), which becomes aberrantly activated but not degraded, leading to prolonged proliferative signaling. Recent studies show that these two signaling pathways may actually converge and integrate. Specifically, Goldkorn et al. demonstrated that during CS exposure, EGFR is favorably co-localized in ceramide-enriched regions of the plasma membrane, proposing that nSMase2/ceramide plays a role in the aberrant EGFR activation, leading to augmented tumorigenic signaling. Moreover, new findings indicate that CS exposure may induce resistance to the tyrosine kinase inhibitors (TKIs), used for treatment of NSCLC, merely through posttranslational molecular alterations. Furthermore, structural anomalies of the CS-activated EGFR appear to be supported by the excess ceramide produced by the CS-activated nSMase2 in the plasma membrane of lung epithelial cells. We present in this chapter the progression of the sphingolipid field in lung cancer using ceramide as an example. However, many crucial questions remain to be answered regarding the role of sphingolipids in lung cancer because of the glut of promising observations.

KW - Ceramide

KW - Cigarette smoke

KW - Egfr

KW - Lung cancer and injury

KW - Neutral sphingomyelinase 2

KW - Oxidative stress

KW - Sphingolipids

UR - http://www.scopus.com/inward/record.url?scp=84880524731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880524731&partnerID=8YFLogxK

U2 - 10.1007/978-3-7091-1511-4-5

DO - 10.1007/978-3-7091-1511-4-5

M3 - Chapter

SN - 9783709115107

VL - 216

T3 - Handbook of Experimental Pharmacology

SP - 93

EP - 113

BT - Handbook of Experimental Pharmacology

ER -